CHARLOTTESVILLE, Va., August 11, 2026   — Quad-C Management, Inc. (“Quad-C”), a leading middle market private equity firm, today announced its investment in Paradigm HSE (“Paradigm” or the “Company”), a leading provider of health and safety solutions to industrial customers across North America. Terms of the transaction were not disclosed.

Formed through the combination of Code Red Safety, Concept Controls, and HazTek, Paradigm has built a differentiated, tech-forward platform spanning technical safety services, safety management, and safety equipment distribution. The Company’s approximately 700 employees support customers throughout the United States and Canada.

Quad-C is partnering with Paradigm’s executive management team, who will remain in their current roles and are maintaining significant ownership in the Company. The partnership should allow Paradigm to reinvest capital to accelerate growth both organically and through strategic acquisitions.

“Paradigm has built a differentiated, client-first culture that, when paired with a commitment to technology-enabled safety solutions, has generated tremendous results” said Jack Walker, Partner at Quad-C. “Nick and his team have demonstrated an impressive track record of growth across each of Paradigm’s pillars, and we see substantial opportunity ahead. We’re excited to support the next phase of the Company’s growth.”

“Quad-C has a long history of investing in commercial and industrial services businesses, and worker safety is a theme we’ve been looking to invest behind for some time,” said Matt Sorensen, Vice President at Quad-C. “We’re excited to partner with Nick and the broader Paradigm team as they continue to build the leading platform in HSE services.”

“From our first conversations with the Quad-C team, it was clear we shared the same values and the same vision for where Paradigm can go,” said Nick Mowbray, CEO of Paradigm HSE. “Quad-C’s support gives us the resources to continue building a market-leading, full-service HSE company. We’re excited about what’s ahead and remain focused on delivering even more value to our customers every day.”

Harris Williams served as financial advisor to Paradigm HSE and Stifel served as buyside advisor to Quad-C on the transaction.

ABOUT QUAD-C MANAGEMENT
Founded in 1989 and headquartered in Charlottesville, Virginia, Quad-C is a middle market private equity firm focused on investing in established services and industrials companies. In its three-decade history, Quad-C has invested $5.3 billion of capital in 92 platform companies and over 425 add-on acquisitions. The Quad-C team is committed to partnering with entrepreneurs and management teams to accelerate growth and create long-term value. For more information, please visit www.quadc.com.

ABOUT PARADIGM HSE
Based in Houston, TX, Paradigm HSE offers safety services, products, and rentals throughout North America. Paradigm’s offerings include safety and health staffing, training and consulting, a wide range of technical safety services, as well as the distribution and rental of equipment across safety, environmental and industrial hygiene applications. As a trusted partner for providing safety, health and environmental solutions to customers, Paradigm is built on ensuring it offers exceptional service, advice, and products across its customer base. For more information, please visit www.paradigmhse.com.

SOURCE Quad-C Management, Inc.

Apollo S3, Pantheon and SQ Capital to join an Exponent-led continuation vehicle dedicated to H&MV Engineering

H&MV FY26 revenues expected to close at more than €1 billion, with a €2 billion order book and a €16 billion pipeline

Transaction provides long-term capital backing to support H&MV’s U.S. expansion, continued hiring, strategic acquisitions and ambition to reach €3 billion in annual revenues

Company plans to grow its global workforce to 3,000

LIMERICK, Ireland and LONDON, Aug. 11, 2026 — H&MV Engineering, a global provider of specialist high-voltage engineering and critical power infrastructure services, today announced the signing of a transaction to establish a continuation vehicle of approximately €750 million, led by existing investor Exponent.  The transaction extends Exponent’s investment in H&MV and brings in Apollo S3, Pantheon and SQ Capital as investors to support the company’s next phase of international growth.

The new investment structure provides long-term capital backing for H&MV’s continued expansion in the U.S., recruitment across its international operations, investment in new engineering capabilities and strategic acquisition opportunities.

Supported by a €2 billion order book, a €16 billion pipeline and long-standing customer relationships, the company is targeting revenues of €3 billion within five years and a global workforce of 3,000 employees. Since 2020, H&MV has increased revenue from €61 million to an expected €1 billion in FY26. During the same period, the company expanded its workforce from 300 to over 1,900 employees today.

Global demand for critical power infrastructure is accelerating as AI, electrification, battery energy storage and the energy transition reshape electricity systems worldwide. H&MV Engineering designs, builds and energises high-voltage infrastructure that enables data centres, battery energy storage and electricity networks, working with leading hyperscale technology companies, co-location providers, utilities and renewable energy developers.

As part of the next phase of its U.S. growth strategy, H&MV will open its North American headquarters in Dallas later this year. Since establishing a presence in the U.S. in late 2025, the company has continued to invest in senior leadership, engineering, project delivery and corporate development capabilities to support its growing operations across the region.

P.J. Flanagan, CEO, H&MV Engineering, said: “This transaction gives H&MV the long-term backing to scale at the pace of the markets we serve and to deliver on our five-year growth ambition. Exponent’s continued support, together with new investment from international investors, will help us accelerate our global expansion, pursue strategic acquisitions, and invest in the capabilities, technologies and people our clients need.”

“Today is a strong endorsement of what we’ve built at H&MV over almost 30 years and I’m incredibly proud of what our team has achieved. As we enter our next phase of growth, we’ll continue investing in the team, our engineering capability and the culture that has enabled us to grow while delivering for clients around the world.”

Tim Easingwood, Partner at Exponent, commented: “H&MV is exactly the kind of ambitious, entrepreneur-led business that Exponent is proud to partner with. This continuation vehicle is a significant milestone for both H&MV and Exponent, and reflects the quality of the business, its exceptional management team and the important role it plays in supporting critical infrastructure globally. We are delighted to welcome Apollo S3, Pantheon Ventures and SQ Capital alongside a high-quality group of institutional investors as we continue our partnership with P.J. and his team. We remain a committed, long-term partner and are excited by the opportunity ahead.”

John Moore, Operating Partner at Exponent and Chair of H&MV Engineering, said: “H&MV has built a unique position at the centre of some of the world’s fastest-growing infrastructure markets, where demand for specialist engineering expertise and reliable power infrastructure continues to increase. The business has built a strong platform from which to serve customers across multiple geographies, while retaining the technical excellence and customer focus that have underpinned its success. Our priority now is to build on those foundations by accelerating H&MV’s U.S. expansion, deepening relationships with global customers and continuing to invest in the people and capabilities required for the next phase of growth.”

The transaction is subject to regulatory approval and formal completion, which is expected in September 2026.

Lazard acted as financial adviser to H&MV and Exponent in connection with the transaction. Arthur Cox and White & Case acted as legal advisers to H&MV.

About H&MV Engineering

H&MV Engineering is a global leader in high-voltage electrical engineering, delivering turnkey solutions for energy, data centre, and industrial infrastructure. With a strong focus on safety, innovation, and sustainability, we are powering the transition to a greener future.

H&MV currently has over 24 GW of projects in design and construction and operates from 20 international offices across Ireland, the UK, Europe, the U.S. and Asia.

With over 1,900 employees and offices spanning three continents, we continue to set industry benchmarks while fostering a culture of safety, teamwork, and respect. For more information, visit www.hmvengineering.com.

About Exponent

Exponent is a European private equity firm that partners with ambitious management teams to accelerate the growth of established mid-market businesses. Primarily investing in family- and founder-led companies and corporate carve-outs, Exponent combines capital with sector expertise, operational insight and an extensive industrialist network to help businesses realise their full potential. From its offices in London and Dublin, Exponent works collaboratively with management teams to unlock new growth opportunities, enhance operational performance and create long-term value.

Exponent has been investing in Ireland based businesses since 2012 and this was further supported with the opening of its Dublin office in 2023. Since its inception in 2004, Exponent has raised five funds and invested in over 40 businesses across Ireland, the UK and Benelux.

To learn more, visit www.exponentpe.com.

About Apollo S3

S3 is Apollo’s Sponsor & Secondary Solutions business. S3 provides flexible capital solutions to asset managers and limited partners across the risk-reward spectrum. S3 is a natural extension of Apollo’s global investment platform, offering partner-oriented capital across asset classes including private equity, private credit, infrastructure and real estate. The S3 platform has raised approximately $14 billion in total capital since launching in August 2022. To learn more about S3, please visit https://apollos3.com/.

About Pantheon

Pantheon has been at the forefront of private markets investing for more than 40 years, earning a reputation for providing innovative solutions covering the full lifecycle of investments, from primary fund commitments to co-investments and secondary purchases, across private equity, infrastructure, and private credit. For more information, please visit www.pantheon.com. 

We have partnered globally with institutional investors of all sizes as well as a growing number of private wealth advisers and investors, with approximately $84bn in discretionary assets under management (as of December 31, 2025).

Leveraging our specialized experience and global team of professionals across Europe, the Americas, and Asia, we invest with purpose and lead with expertise to build secure financial futures.

About SQ Capital

SQ Capital is a modern secondaries firm designed to deliver alpha. We target best-in-class returns across GP-led and LP secondaries, focusing on the middle market. Our team draws on an elite direct investing pedigree, cutting-edge data and AI capabilities, an insider’s understanding of private equity GPs and their portfolios, and deep GP relationships. We combine these strengths with an entrepreneurial mindset to move quickly and with conviction to raise the bar in the secondary market. SQ Capital is headquartered in New York City. For more information, please visit www.SQCapital.com.

Media contacts
H&MV Engineering
Deirdre Connolly, Edelman, [email protected], +353 852449804

Exponent Ireland media enquiries:
Eavan Gannon / Colm Woods, Sodali & Co. – [email protected] 

The company will direct proceeds primarily toward research and large-scale training of its next generation of biological foundation models, further strengthening performance on core tasks such as de novo molecular design, biological structure modeling and function prediction. Aureka will also upgrade Lab-in-the-Loop, its experiment-centered feedback engine, strengthening the closed-loop between those models and its proprietary single-cell functional screening, high-throughput experimental validation and drug development platforms.

With its closed-loop, AI-native infrastructure already built, Aureka is now strengthening the intelligence core of that system: its foundation models. Aureka combines large-scale pre-training, project-specific post-training, AI agents and experiments that run at scale into AI-for-Science infrastructure for the life sciences. In it, models do not just solve individual drug discovery tasks; they learn the rules of biology, to understand, generate, predict and intervene in complex biological systems.

As foundation models and automated R&D converge, Aureka is shifting from using AI to make drug discovery more efficient to using AI to model living systems, pushing both the technical frontier and the commercial ceiling of AI-driven drug discovery.

Closed-Loop AI-Native Infrastructure Builds a Stronger Intelligence Core

Founded in 2023, Aureka Biotechnologies is an AI-native TechBio company developing a new generation of biological foundation models and closed-loop infrastructure that surrounds them, combining AI models, agents, digital biology and experimental platforms to redesign the drug discovery process end to end.

Biology does not yield to computation alone; it depends on feedback from the physical world. Sustained improvement in large biological models requires more than advances in compute, algorithms and model architecture. It also takes high-quality experimental data that faithfully reflects molecular function, and an experimental system able to continuously test model hypotheses, correcting model bias and feeding results into the next iteration.

Aureka therefore treats Lab-in-the-Loop as core infrastructure for model development, integrating AI agents, high-throughput digital biology, proprietary single-cell functional screening and its in-house experimental platform. The resulting loop runs from molecular generation through experimental design, functional validation and model post-training to candidate development.

In this system, the laboratory is no longer a validation step that follows model output; it is a core part of how the model learns and improves. Models propose experimentally testable molecular designs and scientific hypotheses; the experimental platform generates high-quality functional data; and that data flows back into both the foundation model and project-specific models, driving continuous iteration into the next round of design and validation.

This Lab-in-the-Loop mechanism lets Aureka generate its own large-scale, information-dense functional experimental data for use in foundation model pre-training, reinforcement learning and project-specific post-training. Compared with development paths that rely mainly on public, static datasets, Aureka’s models receive experimental feedback from live drug discovery programs and evolve through a continuous design–validation–learning cycle — a flywheel in which data, models, experiments and drug assets reinforce one another.

Foundation Model Capability Confirmed by Third-Party Evaluation

That infrastructure produced AuraIDE, Aureka’s own biological foundation model. Trained at scale on proprietary protein co-evolution data, it learns how protein sequence, structure, evolution and function relate to one another. On biomolecular structure prediction and de novo molecular design, it now ranks among the leaders.

Rather than a single-purpose algorithm, AuraIDE is built to transfer across multiple drug discovery programs through task adaptation and project-specific post-training. Its capabilities extend from protein structure modeling and molecular generation into biomolecular interaction modeling, function prediction and multi-objective optimization under complex design constraints.

OpenDDE, the open-source version of AuraIDE, ranks among the world’s leading open-source biomolecular models in independent third-party evaluations.

Together, the third-party evaluations and the wet-lab results indicate that Aureka’s models lead on protein structure prediction and de novo design, and can translate that capability into measurable molecular function. Through continuous Lab-in-the-Loop feedback, they are moving from predicting biological structure toward generating biomolecules with intended function.

Diversified Commercialization Turns Model Capability into High-Value Drug Assets

Building on its biological foundation models, proprietary single-cell functional screening platform and project-specific post-training, Aureka has produced high-value, differentiated antibodies at scale for problems that conventional approaches struggle with — from difficult target classes such as GPCRs to dual-target antibodies that require a single molecule to engage two targets.

Within a given program, Aureka post-trains its foundation model around target mechanism, functional phenotype and developability objectives, converting general biological intelligence into a dedicated model for a specific drug discovery problem. AI agents then work together across target understanding, molecular generation, computational assessment, experimental design and results analysis, with the resulting experimental data feeding back into that program’s model.

The company’s end-to-end, agentic R&D infrastructure connects molecular generation, developability assessment, experimental validation, results feedback and candidate development, allowing scientific hypotheses, model capability and experimental capacity to be converted rapidly into developable drug assets that support both internal pipeline programs and external collaborations.

Aureka has established strategic partnerships with multiple leading global pharmaceutical companies to advance the development of differentiated antibody therapeutics, and has generated tens of millions in revenue over the past two years — evidence of the platform’s delivery capability, scalability and commercial potential in live drug discovery programs.

From Step-Level Efficiency to Simulating Biological Systems: Toward a Biological World Model

“When leading biological foundation models are genuinely combined with R&D infrastructure that can run at scale, we are no longer simply making one step of drug discovery more efficient — we are building the next-generation drug discovery engine, one that can understand, generate and predict biological systems,” said Dr. Weian Zhao, Founder and Chief Executive Officer of Aureka Biotechnologies. “This is a critical step in Aureka’s progress toward a biological world model.”

On Aureka’s long-term roadmap, a biological world model does more than predict static molecular structures. It will simulate interactions between molecules, reason about the likely outcomes of molecular design and engineering, and support AI agents that plan, execute and iterate on drug design tasks autonomously.

With this financing, Aureka will further advance the co-evolution of its biological foundation models and closed-loop AI-native infrastructure, accelerate the validation and translation of model capability in live drug discovery programs, and continue to expand what generative AI can do in antibody drug development.

Investor Perspectives

Granite Asia, Yinghui Kuang:

“AI-driven drug discovery is moving beyond competition on isolated model capability and into a new phase defined by the co-evolution of data, models and experiments in a closed loop. Aureka has built complete AI-native R&D infrastructure with leading biological foundation models as its intelligence core, giving it the systemic ability to generate high-quality data continuously, iterate its models and convert them into drug assets. We are optimistic about the company’s long-term technical ceiling in generative antibody design and its potential to grow globally.”

HighLight Capital (HLC):

“We are delighted to have completed our investment in Aureka. The company is working to deeply integrate generative AI algorithms with high-throughput wet-lab platforms, with the potential to reshape the paradigm for biologics R&D. We think highly of the team’s deep technical foundation in AI-enabled drug development and the efficiency of its closed loop. Going forward, we will continue to commit resources to help the company accelerate pipeline progress and technology iteration, and to bring AI to drug innovation worldwide.”

MPCi, Yuye Wang:

“Aureka is a team we backed early and have continued to believe in. OpenDDE, the open-source all-atom model it released, demonstrates this young team’s foresight in AI drug discovery and the strength of its technical foundations. Together with the differentiated pipeline the company has now built, we believe a team that combines innovative edge with strategic discipline will keep breaking through bottlenecks in drug development and bring genuine paradigm change to the industry.”

NRL Capital:

“Aureka is defining the infrastructure standard for AI drug discovery. The open-source release of OpenDDE marks a key transition from innovation to systematic platform building, closing the loop between computational models and ultra-high-throughput automated wet-lab work and establishing Aureka’s global voice in native infrastructure for broadly accessible drug discovery. We recognize the strategic vision of Dr. Weian Zhao and his team in driving industry change through an open-source ecosystem, and we are firm believers in the exponential gains that a dry-lab/wet-lab closed loop delivers in antibody design efficiency. NRL Capital has completed a follow-on investment in this round and will continue to support the company’s global expansion and the realization of the global value of its AI infrastructure.”

About Aureka Biotechnologies

Aureka Biotechnologies is an AI-native TechBio company building next-generation biological foundation models and closed-loop AI-native infrastructure to transform the therapeutic discovery process. The company has raised nearly $200 million to date and established strategic partnerships with multiple leading global pharmaceutical companies to advance the development of novel antibody therapeutics. Aureka’s proprietary foundation model, AuraIDE, is trained on its internal protein co-evolution data and has demonstrated leading capabilities in protein folding and de novo design. Its open-source version, OpenDDE, ranks among the world’s leading open-source biomolecular models in independent third-party evaluations.

About Granite Asia

Granite Asia is Asia’s most trusted private capital platform, partnering with visionary founders and leaders to build industry champions. With USD 10 billion in assets under management and co-managed capital, the firm has invested in 127 companies valued at over USD 1 billion and supported 67 IPOs worldwide.

About HighLight Capital (HLC)

HighLight Capital (HLC) is a private investment firm dedicated to creating long-term values through promoting technology innovations. Leveraging deep expertise in chemical, biological and materials sciences and proprietary industry research, we invest in companies that enhance manufacturing efficiency and improve human wellness. HLC currently manages over US$4.2 billion.

About MPCi

Founded in 2008, MPCi is one of the leading venture capital firms focused on early stage and early growth deals in China, now managing over 70 billion RMB. MPCi mainly invests in new economy, deep technology, industrial digitalization, healthcare, frontier technology and new consumer brands. MPCi has over 40 investment professionals with deep sector knowledge. The firm also established one of the largest portfolio management teams in the market. Over 80 professionals formed 10 different functions including strategy and operation consulting, recruiting, and healthcare services, etc., to provide value added services to entrepreneurs.

About NRL Capital

NRL Capital is a long-term capital platform that unites top-tier domestic and international industry resources. The firm has built an integrated investment and fund management platform with three interconnected capabilities — direct investment, private equity secondaries, and fund-of-funds — powered by dual-currency operations in both onshore RMB and offshore USD. NRL Capital is deeply focused on pharmaceuticals, medical devices, life sciences, and advanced manufacturing.

SOURCE Aureka

-NdotLight builds data infrastructure that can be directly used for physical AI training simulations

-Validating its business potential and laying the foundation for global growth; actively hiring across all functions

-NAVER D2SF makes its third investment following initial investments in 2021 and 2022, continuing long-term support and exploring collaboration opportunities in physical AI data

SEONGNAM, South Korea, Aug. 10, 2026 — NAVER D2SF, the corporate venture capital arm of NAVER, has made a follow-on investment in NdotLight (CEO, Jinyoung Park), a data infrastructure company for physical AI. The KRW 15 billion funding round was led by Korea Development Bank. This marks NAVER D2SF’s third investment in NdotLight, following its participation in the company’s Pre-Series A round in 2021 and Series A round in 2022. NAVER D2SF decided to make this additional investment based on NdotLight’s potential to address data, one of the key bottlenecks in physical AI.

NdotLight has developed TRINIX, a “simulation-ready” 3D data generation solution that can be directly applied to physical AI training simulations. As data becomes increasingly critical to physical AI, various approaches such as teleoperation have been explored. However, significant gaps in data quality, slow collection speed, and high costs have remained major bottlenecks when applying such data to simulation environments where real-world AI training takes place.

NdotLight addresses this challenge through an automated pipeline that generates 3D data with detailed physical properties such as mass and friction, as well as joint structures and collision boundary information. In particular, TRINIX integrates with NVIDIA Omniverse, NVIDIA’s simulation platform, enabling the company to supply large-scale, high-quality 3D simulation datasets.

NdotLight currently provides AI training data to humanoid robotics and robotics foundation model companies, including Holiday Robotics, AeiRobot, ROBROS, and RLWRLD. The company is also participating as a data supplier in physical AI projects led by major enterprises such as Hyundai Motor Company and LG Electronics, validating its business potential as data infrastructure that can be applied in real-world industrial settings.

The NdotLight team brings strong technical and business expertise across AI and 3D graphics. CEO Jinyoung Park previously worked on 3D launcher development at Samsung Electronics, while CTO Suntae Kim led AI and 3D engine development at NAVER and Samsung Electronics. NdotLight has also been named by CB Insights, a global venture research firm, as one of the world’s notable 3D engine companies. With this latest funding, the company is actively hiring top talent across all functions.

NAVER D2SF has built long-term partnerships with frontier startups by providing venture capital at the early stage and continuing to support their growth through follow-on investments. Since its first investment in NdotLight in 2021, NAVER D2SF has worked closely with the company to build a 3D content creation environment, followed by a subsequent investment in 2022. Through this additional investment, NAVER D2SF plans to explore new collaboration opportunities with NdotLight in physical AI.

“NdotLight is a team that has built deep trust with NAVER D2SF not only through our investments, but also through close collaboration as a resident startup at NAVER 1784,” said Sanghwan Yang, Head of NAVER D2SF. “The team has consistently identified key opportunities ahead of fast-changing market shifts and moved quickly to execute on them. We expect NdotLight to take its next leap as a leading physical AI data company and achieve even greater growth.”

NAVER D2SF is NAVER’s in-house corporate venture arm, supporting sustainable growth by collaborating with startups. Founded in 1999, NAVER has maintained its position as Korea’s leading search engine for over 20 years and operates across commerce, content, fintech, and cloud services. Under the technological vision of D2SF, NAVER is actively developing new technologies and global partnerships to grow as a leading tech company. To learn more, visit https://d2sf.naver.com

SOURCE NAVER D2SF

SEATTLE, Aug. 10, 2026 — Lightview Capital announced today a strategic investment in InStore Technology, a leading provider of managed technology for independent grocers across the western United States. Headquartered in Seattle, WA, InStore Technology partners with independent and regional grocery chains to deliver mission-critical, end-to-end retail technology infrastructure and 24/7 support.

The partnership with Lightview Capital will accelerate InStore’s growth strategy, supporting enhanced service capabilities, continued geographic expansion, and strategic acquisitions. Together, the companies plan to build upon InStore’s strong foundation as a trusted provider of mission-critical retail technology and managed services.

Tom Courlas, CEO of InStore Technology, commented, “The team at Lightview Capital has the track record and skillset to assist us in expanding our capabilities and presence to bring the highest quality support to independent retailers.”

“We’re excited to be teaming up with Tom and the InStore team on its next phase of growth,” said Stan Bikulege, Principal at Lightview Capital. “InStore has a differentiated approach to helping its customers solve the challenges associated with a rapidly changing technology, compliance, and cybersecurity landscape. Our partnership with InStore will allow the company to continue to capitalize on a large and growing market opportunity within the retail sector.”

Richard Erickson, Co-founder and Managing Director at Lightview Capital, added: “InStore Technology represents the kind of entrepreneurial, service-driven platform we’re proud to back. The combination of their service model and our expertise in the managed IT services sector, aligns perfectly with Lightview’s approach to building long-term value.”

Klar Ventures principals served as financial advisor to InStore Technology.

About InStore Technology
InStore Technology is a leading provider of retail technology and managed services serving independent and regional grocers across the western United States. The company designs, installs, and supports point-of-sale, self-checkout, electronic shelf label, cybersecurity, and other technology systems. InStore is dedicated to delivering mission-critical infrastructure and exceptional service to the grocers it serves.
For more information, visit https://www.instoretech.com/.

About Lightview Capital
Lightview Capital is a leading private equity firm focused on investing in founder-owned companies in the business services and tech-enabled services industries. Lightview partners with its portfolio companies by providing deep industry knowledge, insightful experience, and active resources to unlock growth and drive value. For more information, visit www.lightviewcapital.com.

Contact for Lightview Capital
Laurel Vermette
[email protected]

SOURCE Lightview Capital

Oversubscribed financing scales the restaurant commerce platform connecting more than 5 million diners with more than 8,500 restaurants that collectively represent nearly $30 billion in annual restaurant GMV

Citi’s participation builds on its existing relationship with inKind, as its venture capital arm, Citi Ventures, invested in the company in 2025.

AUSTIN, Texas, Aug. 10, 2026 — inKind, the curated restaurant commerce platform helping great restaurants access capital, guests, and technology, today announced the closing of an oversubscribed $414 million second financing tranche led by Citi and Cross River alongside Sagard, Varadero Capital, and Trinity Capital. The transaction brings inKind’s total capital raised to more than $1.2 billion.

Just as Airbnb built infrastructure connecting hosts and travelers, and DoorDash built infrastructure connecting merchants and consumers, inKind is building growth infrastructure that connects restaurants with capital and high-intent guests. Its platform combines upfront capital, demand generation, financial tools, guest rewards, proprietary data, and AI-native capabilities. Today, inKind’s curated network connects more than 5 million diners with more than 8,500 restaurants that collectively represent nearly $30 billion in annual restaurant GMV.

The new commitments include:

Senior

• Citi: $175 million
• Cross River: $150 million

Mezzanine

• Sagard: $50 million
• Varadero Capital: $25 million
• Trinity Capital: $14 million

The closing follows Liberty Mutual Investments’ recently announced $320 million commitment as a senior anchor and mezzanine lender. With the expanded facility, inKind plans to deploy more than $1 billion in growth capital to nearly 10,000 restaurants over the next year.

The transaction marks a major milestone for inKind and the restaurant industry, bringing institutional scale to a model designed to help high-quality restaurants access growth capital while creating incremental guest demand. It also expands the capital foundation behind a commerce platform that becomes more valuable as more restaurants and diners join and its proprietary data advantage deepens.

“For more than a decade, inKind has been building a new way to finance and grow great restaurants,” said Johann Moonesinghe, co-founder and CEO of inKind. “When Rajan Moonesinghe, Andy Harris, Jonathan de Wolff and I started the company, we had to use our own capital to fund restaurants because we were building a model the market had not yet seen. It took years of performance, discipline, and proof before institutional investors began to understand the asset class we were creating. The addition of Citi, a global systemically important bank, is an important signal that the market increasingly recognizes the strength of the inKind model. This financing gives us the capacity to scale the restaurant commerce infrastructure we have spent more than a decade building.”

inKind provides restaurants with upfront growth capital and connects them with millions of high-intent guests through its curated dining network. By combining capital, commerce, demand generation, rewards, and technology on one platform, inKind helps operators create incremental revenue, build repeat customer relationships, and grow without relying solely on traditional debt, dilutive equity, or discount-driven marketing.

inKind is highly selective about the restaurants it brings onto the platform. The company focuses on restaurants guests are likely to love and want to experience again — from nationally recognized restaurant groups to standout independent operators. That selectivity is central to the strength of the model: guests trust inKind as a way to discover exceptional restaurants, operators benefit from access to quality demand, and capital providers gain exposure to a curated network designed for durability.

Since 2022, inKind has grown from approximately 1,000 restaurant partners to more than 8,500 today, collectively representing nearly $30 billion in annual restaurant GMV. The company has also grown from approximately 1 million users in March 2024 to more than 5 million users today, creating one of the largest curated restaurant networks in the United States.

“The proof is in the quality of the network,” Moonesinghe continued. “Some of the best restaurant operators in the country trust inKind, and millions of guests use our platform to discover, support, and return to great restaurants. That combination of restaurant quality, guest scale, capital infrastructure, and proprietary data is what makes inKind different.”

Building a New Commerce Model for Great Restaurants

Restaurants are one of the largest and most important sectors in the U.S. economy, but even great operators have historically lacked a growth platform designed around how restaurants actually operate. Traditional debt can be expensive and restrictive. Equity can be dilutive. Discount-driven marketing can damage brand equity and train guests to value promotions more than the restaurant itself.

inKind was built by restaurant operators to give great restaurants a better way to grow.

The company’s platform combines upfront capital, demand generation, guest rewards, financial tools, and AI-native technology designed to help restaurants bring the right guests into the room at the right times. For operators, inKind creates access to growth capital and incremental guest demand without requiring conventional debt service or ownership dilution. For guests, inKind provides a smarter way to discover exceptional restaurants, support the people behind them, and earn more toward their next experience.

Today, inKind partners with nationally recognized groups such as MINA Group, Ethan Stowell Restaurants, and José Andrés Group, as well as acclaimed independent operators including Okàn, Kann, and Superiority Burger. The company has provided more than $850 million in growth capital to restaurant partners and delivered more than $225 million in dining rewards to guests.

Institutional Capital Behind a Scalable Restaurant Platform

The new tranche significantly expands the group of institutional investors supporting inKind’s growth.

Together with Liberty Mutual Investments debt investment, the new financing provides inKind with additional long-term capacity to support restaurant operators nationwide and further validate the company’s model as an emerging institutional asset class.

inKind’s selectivity is central to both its credit model and its network economics. By focusing on strong operators and restaurants that guests are likely to love, revisit, and recommend, inKind protects guest trust and builds a network designed for durability. Better restaurants create stronger guest demand and engagement; stronger demand makes the platform more valuable to operators and more resilient for capital providers.

“This is bigger than a financing milestone for inKind,” said Moonesinghe. “It represents growing recognition that great restaurants are essential businesses, major employers, and anchors of their communities — and that they deserve a capital model designed specifically for how they operate.”

Scaling the Restaurant Growth Infrastructure

inKind is building a growth operating system for restaurants by combining capital, consumer demand, technology, financial tools, proprietary data, and AI-native capabilities on a single platform.

Because inKind operates across thousands of restaurants and millions of guests, its platform can identify patterns, demand opportunities, and guest behavior that no single restaurant group — no matter how sophisticated — could see on its own. The company believes that combining this network-level data with recent advances in artificial intelligence can create a new level of growth infrastructure for restaurants, helping operators make more informed decisions about capital, guest acquisition, demand generation, and long-term growth.

“Restaurants are among the most important engines of local job creation in America,” said Moonesinghe. “When a great restaurant grows, it creates opportunity for chefs, servers, bartenders, managers, suppliers, landlords, and the neighborhoods around them. Restaurants are also the rooms where communities gather — where birthdays, anniversaries, first dates, family dinners, and ordinary nights become lifelong memories. Our mission is to help more great restaurants open, expand, create jobs, and remain part of their communities for generations.”

Moonesinghe added: “We believe inKind is still in the early chapters of what it can become. As our restaurant network grows, we can give more great operators access to millions of guests. As our guest base grows, we can give more diners access to the best restaurants in the country. That flywheel is what we have spent the last twelve years building.”

About inKind
Founded in 2014, inKind is a curated restaurant commerce and growth platform built to help great restaurants thrive and give guests more reasons to gather around the table. Built by restaurant operators for restaurant operators, inKind provides upfront capital and demand tools that help restaurants bring in the right guests at the right times, while giving diners a smarter way to discover exceptional restaurants, support the people behind them, and earn more toward their next experience.

inKind is highly selective about the restaurants it brings onto the platform because guest trust is central to the network. By partnering with restaurants guests are likely to love, revisit, and recommend, inKind helps operators create incremental revenue while giving diners confidence that every inKind experience is worth planning around. Today, inKind connects more than 5 million guests with more than 8,500 restaurants across the United States. Those restaurants collectively represent nearly $30 billion in annual restaurant GMV. The company has provided more than $850 million in capital to restaurant partners and delivered more than $225 million in dining rewards to its users.

Learn more at inKind.com and follow @inkind.app.

Media Contact: [email protected]

SOURCE inKind

Investment supports advancement of Remedium’s durable protein therapeutics platform toward first-in-human clinical development.

NORWALK, Conn., Aug. 10, 2026 — Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.’s (“Remedium”) $10 million Series A financing and has completed the round’s initial closing, with participation from Eli Lilly and Company (“Lilly”) and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium’s Board of Directors.

Remedium is developing durable protein therapeutics designed to enable controlled, long-lasting expression of therapeutic proteins following minimally invasive subcutaneous administration. The company’s approach harnesses adipocytes as a durable site for therapeutic protein production, with the potential to provide multi-year benefit and adjustable dosing for patients with chronic diseases.

The financing will support advancement of Remedium’s lead programs, continued platform expansion, and preparation for first-in-human clinical studies.

“Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy,” said Andrew Worden, Founding Partner of Lifespan Vision Ventures. “We are proud to lead the Series A financing and support the company as it advances its pipeline toward clinical development and expands the potential of its platform.”

“Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease,” said Frank Luppino, Chief Executive Officer of Remedium Bio. “We are excited to have them lead our Series A and to welcome Harry Robb to our Board as we advance our platform, expand our pipeline, and prepare for first-in-human clinical development.”

The financing follows recent progress across Remedium’s pipeline, strategic collaborations, and preclinical programs, and is expected to support key milestones demonstrating the breadth of its platform across cardiometabolic and other chronic diseases.

About Lifespan Vision Ventures

Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven solutions that promote healthy aging and extend human healthspan.

Contact: [email protected] 

About Remedium Bio, Inc.

Remedium Bio is a biotechnology company driven by the belief that any disease can be cured. The company develops life-changing therapeutics for large unmet medical needs by advancing a revolutionary gene therapy platform that enables safe, effective, and durable delivery of therapeutic genes with simple post-treatment dose adjustment. Remedium’s proprietary Prometheus™ platform aims to replace many subcutaneously administered protein therapies with single-injection, adjustable gene therapies that offer long-lasting efficacy at a fraction of the cost. The company’s pipeline includes programs targeting endocrinology, immunology, neurology, and musculoskeletal diseases.

For more information, please visit www.remedium-bio.com or contact [email protected] 

SOURCE LifeSpan Vision Ventures

Strategic partnership set to advance commercialization of deployable small modular reactor technology for critical energy infrastructure

HOUSTON, Aug. 10, 2026 — Deployable Energy today announced that Solaris Energy Infrastructure, Inc. (NYSE: SEI) (“Solaris”) has made an equity investment in the company and intends to collaborate with Deployable Energy on the commercialization of its deployable microreactor technology.

The investment was announced by Solaris as part of its second quarter 2026 business update. In its announcement, Solaris stated that it has “made an equity investment in Deployable Energy, providing early exposure to next-generation nuclear technology” and that it “will work with Deployable on commercialization of their SMR technology, complementing our existing generation capabilities.”

The relationship combines Deployable Energy’s mission to deliver transportable, resilient nuclear power with Solaris’ experience deploying, operating, and maintaining distributed energy infrastructure for mission-critical applications. As demand for reliable, always-on power continues to accelerate across defense, industrial, and digital infrastructure markets, the companies see opportunities to explore how advanced nuclear energy technologies can complement existing power solutions.

“We’re excited to welcome Solaris as both an investor and strategic collaborator,” said Bobby Gallagher, CEO and Co-Founder of Deployable Energy. “Solaris has established itself as a leader in delivering reliable power infrastructure for demanding applications. Their investment and commercial perspective validate the growing need for next-generation energy solutions that combine resilience, scalability, and long-duration performance.

The collaboration with Solaris represents an important step for Deployable Energy in building an ecosystem of strategic partners that can help accelerate the commercial deployment.”

“Deployable Energy brings real world execution to a technology the market has talked about for years but few have delivered,” said Bill Zartler, Founder and Co-CEO of Solaris Energy Infrastructure. “The speed they’ve shown getting to first criticality, their differentiated design and approach to avoiding supply chain constraints, gives us confidence that the Deployable Energy team can turn next-generation nuclear products into reality in the relatively near term. We’re excited to be part of this story.”

About Deployable Energy

Factory made nuclear from the energy capital of the world. 

Deployable Energy builds microreactors designed for real-world operations. Our systems are engineered for rapid deployment, simple operation, and reliable power where traditional infrastructure can’t reach.

Learn more at: Deployable.Energy

About Solaris Energy Infrastructure, Inc.

Solaris Energy Infrastructure, Inc. (NYSE:SEI) delivers comprehensive power infrastructure solutions including generation, distribution, installation and commissioning, aftermarket support, and operations and maintenance. Headquartered in Houston, Texas, the Company serves multiple U.S. end markets, including data centers, energy, and other commercial and industrial sectors. Additional information is available on our website, solaris-energy.com.

SOURCE Deployable Energy

WashWise launches Reset Spray, a fabric spray for clothes that are too clean to wash but not fresh enough to rewear

NEW YORK, Aug. 10, 2026 — WashWise, a modern clothing care company redefining how consumers care for garments between wears, today announced it has raised $1.2 million in pre-seed financing through a SAFE round and officially launched its debut product, Reset Spray.

Founded by former J.P. Morgan and Citadel trader Maria Cabral Menezes, WashWise was created around a simple insight: clothing spends roughly 99% of its life outside the washing machine, yet most innovation in clothing care is designed around the washer or the 1% it spends inside the washer. As consumers repeat outfits, travel more, invest in higher-quality clothing, and embrace resale and rental fashion, WashWise is building a new category of between-wear clothing care.

Reset Spray is designed to refresh, de-wrinkle, deodorize, and lightly cleanse clothing between washes, helping consumers extend wear and reduce unnecessary laundry and dry cleaning. Often described as “dry shampoo for clothes,” the formula combines multiple clothing-care functions into one streamlined solution.

“Everyone has experienced the moment where a piece of clothing isn’t dirty enough to wash, but doesn’t feel fresh enough to wear again,” said Maria Cabral Menezes, Founder of WashWise. “We realized there was an entire part of a garment’s life that had been completely ignored.”

The $1.2 million pre-seed funding round includes a strategic syndicate of founders, Wall Street executives, and consumer leaders spanning retail, fashion, hospitality, technology, logistics, and consumer packaged goods. Backers include FJ Labs, Singh Capital, Alex Jekowsky, Jack Abraham, Brian Tate, Gigi Howard, Nina Farran, Mia Tonelli, Taylor James, and Brown Girl Angels, alongside executives and operators from Pickle, The Business of Fashion, Dior, SoulCycle, Soho House, Apple, and J.P. Morgan.

The company will use the financing to accelerate product development, expand strategic partnerships, grow its team, and build awareness around its new approach to clothing care.

Available in Cotton Cooldown and Verde Rise, Reset Spray is skin-safe, plant-derived, non-toxic, and packaged using bag-on-valve technology. One 6oz bottle can help save up to $300 in dry cleaning costs, approximately six hours of laundry time, 110 gallons of water, and 16 kWh of electricity over its use.

Reset Spray (6oz., $29 MSRP) is available now at www.washwise.com in full-size and travel-size.

Media Contact
Brandsway Creative
Tara Ciccone, Partner
[email protected]

SOURCE WashWise